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Objectives. We sought to determine the prognostic significance
of a history of congestive heart failure above that provided by
baseline ejection fraction in patients undergoing percutaneous
coronary interventions.
Background. Left ventricular function is a known predictor of
survival in patients with coronary artery disease, as is a history of
congestive heart failure. The contribution of heart failure history
independent of left ventricular function is unknown.
Methods. Data were pooled from four interventional trials and
the Duke University database. The combined dataset included
5,260 patients undergoing percutaneous interventions, 334 with
and 4,926 without a history of heart failure. Patients were defined
by the treating physician as having a clinical history of heart
failure at the time of enrollment.
Results. The 30-day and 6-month mortality were higher in
patients with a clinical history of congestive heart failure than in
those without such a history (2% vs. <1%, p 5 0.002 at 30 days,
5% vs. 1%, p 5 0.001 at 6 months). Heart failure history did not
influence the incidence of myocardial infarction, use of angio-
plasty or the use of bypass surgery during follow-up. Multivari-
able analysis revealed that heart failure history added signifi-
cantly to ejection fraction in predicting intermediate-term (6-
month) mortality (p 5 0.01). Stepwise logistic regression also
revealed heart failure history to be an independent predictor of
6-month mortality (odds risk 1.9, 95% confidence interval 1.1 to
3.5).
Conclusions. A clinical history of congestive heart failure is
associated with increased early and intermediate-term mortality
in patients undergoing percutaneous revascularization. Conges-
tive heart failure history appears to provide prognostic informa-
tion independent of that available from a patient’s left ventricular
function. These findings suggest that patients with a clinical
history of congestive heart failure who undergo a percutaneous
intervention should be closely monitored, especially those with the
lowest ejection fractions.
(J Am Coll Cardiol 1998;32:936–41)
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The state of the left ventricle is a strong predictor of outcome
in patients with coronary artery disease. Early studies of
patients with coronary artery disease treated medically made
clear that ejection fraction was most closely associated with
survival, an even stronger predictor than the number of
diseased vessels (1,2). A clinical history of congestive heart
failure (CHF) has also been shown to be a significant prog-
nostic factor in this patient population (3,4). Both the clinical
and angiographic predictors, heart failure history and ejection
fraction (EF), have also been shown to be prognostically
important in patients after myocardial infarction (5–7). Data
have suggested that the inverse relationship between EF and
mortality holds even for the right ventricle in the postmyocar-
dial infarction setting (8).
The prognostic significance of EF and heart failure history
have also been shown in other settings. These characteristics
are important to consider in patients undergoing surgical
revascularization (9–12), and are predictive of perioperative
and long-term mortality (13,14) as well as long-term symptom
status after surgical bypass (15). Congestive heart failure
history has been found to predict survival in uncorrected aortic
stenosis (16) and was found to strongly correlate with 1-year
survival in a study of postmyocardial infarction arrhythmia
suppression (17). Many of the clinical and angiographic pre-
dictors of outcome in patients with coronary artery disease
treated medically (and surgically) have also been found to be
important in those who undergo a percutaneous revasculariza-
tion procedure. Ejection fraction has been shown to be prog-
nostically important after coronary angioplasty for unstable
angina in both short- and long-term studies (18–20). A pa-
tient’s left ventricular function (EF) is also prognostically
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significant after angioplasty for acute myocardial infarction
(21).
The presence of CHF is associated with adverse events after
percutaneous revascularization procedures (22,23). In an anal-
ysis from the National Heart, Lung and Blood Institute
(NHLBI) registry of adverse events 8 years after angioplasty, a
history of CHF at baseline was the strongest predictor of
outcome among six clinical characteristics evaluated (24). To
date, the independent contribution of CHF history to the
prediction of morbidity and mortality after percutaneous re-
vascularization has not been evaluated. We therefore studied,
in a pooled analysis of interventional trials, whether a baseline
history of CHF contributed significant information, above that
contained in a patient’s EF, to the prognosis of patients
undergoing percutaneous procedures.
Methods
Patient population. Patients were pooled from four ran-
domized trials (the Perfusion Balloon Catheter Study Group
[PBC] Trial, Coronary Angioplasty Versus Excisional Atherec-
tomy Trial [CAVEAT]-I and -II, Integrelin to Manage Platelet
Aggregation to Prevent Coronary Thrombosis-II [IMPACT-II]
and one interventional (Duke) database. These data were
collected from April 1989 to August 1991 in the PBC trial, July
1991 to July 1992 in CAVEAT-I, March 1992 to September
1993 in CAVEAT-II, November 1993 to November 1994 in
IMPACT-II and between April 1986 and June 1989 in the
Duke dataset. The four trials and prospective cohort combined
include data from 6,602 patients. Of these patients, 5,260 had
both EF and CHF history available and provide the basis for
this analysis.
The randomized trials in this analysis have been published
(25–28). The randomized trial of gradual prolonged (perfu-
sion) vs. standard balloon inflation in elective angioplasty
(PBC trial) provided 547 patients. These patients had stable or
unstable angina. Included were 1,012 patients from the
CAVEAT-I trial of angioplasty vs. directional atherectomy in
native coronary arteries. The data from 305 patients enrolled
in the CAVEAT-II trial of angioplasty vs. directional atherec-
tomy in saphenous vein bypass grafts were also included. The
majority of patients in CAVEAT-I and -II had unstable angina.
The IMPACT-II trial included 4,010 patients undergoing
elective, urgent or emergency percutaneous coronary interven-
tion. More than half of these patients were considered low risk
(58%), while the remainder were enrolled with either unstable
angina (38%) or myocardial infarction (3%).
The interventional database included all patients undergo-
ing elective first-time angioplasty of native coronary artery
lesions screened at Duke University Medical Center. This
process identified 2,176 patients, of which a random sample of
1,056 were included in the database. After exclusion of 328
patients with acute myocardial infarction, 728 remained for
this analysis.
Interventional procedures. All patients in this database
received preprocedural aspirin (325 mg/day) and intraproce-
dural heparin. Patients in the PBC trial also received prepro-
cedural dipyridamole, 75 mg three times daily. All patients
except those in the PBC and IMPACT-II trials received a
calcium-channel blocker for approximately 1 month. All an-
gioplasty and atherectomy procedures were performed using
standard techniques (29,30). The vascular access sheaths were
removed from all patients between 4 and 24 h after the
procedure (4 to 6 h in IMPACT-II) at the discretion of the
treating physician.
Data collection. The data from the four randomized trials
were all collected prospectively on case report forms during
the individual trials and forwarded to the coordinating center
at Duke University. All four trial datasets were verified using
consistency checks and double data entry; sites were queried
about any missing data. Demographic and procedural data
from all patients in the Duke database were collected prospec-
tively and entered into the Duke Databank for Cardiovascular
Disease. The complete dataset was verified by retrospective
review of patient charts. Complete copies of the datasets from
the four randomized trials were combined with the Duke data
into a single database for the purposes of this analysis.
Follow-up. Patients in CAVEAT-I, CAVEAT-II and the
PBC and IMPACT-II trials all had 6-month follow-up for the
clinical events of death, myocardial infarction, repeat angio-
plasty or bypass surgery. In CAVEAT-I and the PBC trial
follow-up continued for up to 1 year. The follow-up of
in-hospital events was performed by retrospective chart review
for patients from the Duke database. Patients were contacted
by telephone or mail to assess their status at 1 year (the
occurrence of death, myocardial infarction, repeat angioplasty
or surgical bypass). The average duration of follow-up on
patients in this study was 8 months. All patients in the
randomized trials underwent protocol recatheterization at 6
months, except in IMPACT-II. All patients with a successful
procedure in the Duke database were asked to return within 6
months for repeat angiography, regardless of symptom status.
Angiography. The initial and follow-up angiograms of pa-
tients in randomized trials were read in a core laboratory by
independent reviewers blinded to treatment. All cineangio-
grams were evaluated by quantitative coronary angiography.
All initial as well as follow-up angiograms of patients in the
Duke database were adjudicated by the consensus of two
observers. In all patients a vessel was considered diseased if it
contained at least one lesion that was more than 50% oc-
cluded. All EF measurements were obtained by ventriculogra-
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phy. In-laboratory and in-hospital (before hospital discharge)
abrupt closure was defined as angiographic evidence of
Thrombolysis In Myocardial Infarction grade 0 or grade 1 flow
in the previously dilated artery. The definition of abrupt
closure for patients in the Duke and CAVEAT-II datasets also
required clinical or electrocardiographic evidence of ischemia.
All patients had angiography at baseline and at 6 months,
excluding those in IMPACT-II. IMPACT-II patients did not
undergo follow-up angiography (28).
Definitions. A clinical history of CHF was defined slightly
differently in each study. The CAVEAT-I and -II and the
IMPACT-II case report forms collected the variable “history
of CHF” as a dichotomous variable (yes/no) with no further
definition. The case report form for the PBC trial also col-
lected whether the patient had a “history of CHF.” In the
Duke dataset, the patient data form collected a variable,
“recent history of CHF,” defined as symptoms of dyspnea or
fatigue not related to an acute myocardial infarction within the
past 6 weeks. A successful procedure was defined as one in
which the residual stenosis in the target vessel was 50% or less.
Restenosis occurred when the target lesion was found to have
more than 50% narrowing on follow-up angiography.
Statistical analysis. All baseline characteristics are pre-
sented as frequencies and percentages for discrete variables
and as medians with 25th and 75th percentiles for continuous
variables. Univariable analysis at 30 days and 6 months was
performed using the likelihood ratio chi-square test. We used
logistic regression analysis to determine the contribution of
baseline EF and heart failure history in predicting the out-
comes of death, myocardial infarction, repeat angioplasty,
bypass surgery or the composite of any of these. Baseline EF
was treated as a continuous variable. Stepwise logistic regres-
sion was also performed to determine the significant predictors
of 6-month mortality. The clinical characteristics used in this
model were EF, history of CHF, number of diseased vessels,
age, sex and diabetes history.
Results
Of 5,260 patients, 334 had a history of CHF and 4,926 did
not. The distribution of devices used in this cohort was 66%
standard angioplasty, 23% directional atherectomy and 11%
prolonged angioplasty with a perfusion balloon. More than a
single interventional device was used in 12% of patients with
and 11% of those without a history of heart failure.
Patients with a clinical history of CHF were older, more
often female and more frequently had angina of a limiting
degree (Table 1). These patients also were more likely to have
other risk factors, including diabetes, hypertension, prior myo-
cardial infarction and a previous revascularization procedure.
As expected, the patients with a clinical history of heart
failure had more significant coronary disease and worse left
ventricular function at baseline (Table 2). However, there were
no differences between the two groups in angiographic out-
comes either early or at the 6-month follow-up (Table 3).
Analyses were performed at both 30 days and 6 months to
assess the impact of CHF history on early and intermediate
clinical end points. Patients who had a clinical history of heart
failure were less likely to survive at either time point (Table 4).
There were no associations between CHF history and the
incidence of myocardial infarction or the occurrence of a
further revascularization procedure at these time points.
Logistic regression revealed that both EF and CHF history
alone were prognostically important when predicting both
30-day and 6-month mortality (Table 5). When heart failure
history was added to the 30-day model of mortality with EF
incorporated, its additional prognostic potential did not reach
statistical significance (p 5 0.20). At 6 months, EF and CHF
history each had a significant ability to predict mortality.
Congestive heart failure history added to the 6-month
mortality model with EF already accounted for; its indepen-
dent contribution was significant (chi-square 6.30, p 5 0.01).
When CHF history was first included in the model, EF added
significantly both at 30 days and 6 months (p 5 0.0001 for
Table 1. Baseline Clinical Characteristics
History of Congestive Heart
Failure
Yes
(n 5 334)
No
(n 5 4,926)
Median age (interquartile range) (yr) 66 (56, 72) 59 (51, 67)
Male sex (n [%]) 204 (61) 3,710 (75)
History of angina (n [%]) 283 (85) 3,950 (80)
Canadian Heart Class angina (n [%])
I 23 (8) 423 (11)
II 58 (21) 1,131 (29)
III 80 (29) 994 (26)
IV 112 (41) 1,297 (34)
Current smoker (n [%]) 58 (22) 1,345 (35)
Any smoking history (n [%]) 221 (66) 3,389 (69)
History of diabetes (n [%]) 129 (39) 973 (20)
Hypertension (n [%]) 212 (64) 2,517 (51)
Previous infarction (n [%]) 232 (69) 2,201 (45)
Previous angioplasty (n [%]) 81 (24) 1,068 (22)
Previous bypass (n [%]) 105 (31) 734 (15)
Table 2. Baseline Angiographic Characteristics
History of Congestive Heart Failure
Yes
(n 5 334)
No
(n 5 4,926)
Number of diseased vessels
1 148 (47%) 2,585 (55%)
2 107 (34%) 1,555 (33%)
3 59 (19%) 522 (11%)
Number of total occlusions 11 (3%) 280 (5%)
Ejection fraction (%) 47 (35, 60) 57 (50, 63)
,30% 54 (16%) 92 (2%)
30% to 40% 83 (25%) 451 (9%)
.40% 197 (59%) 4,383 (89%)
Values are number of patients (percentages) or medians (25th and 75th
percentiles).
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both). Neither EF nor CHF history was a significant predictor
of either the composite or end points other than death at 6
months. Stepwise logistic regression was used to model
6-month mortality, and a history of heart failure was again
shown to be predictive in addition to EF and patient age
(Table 6). There was no interaction between gender and
outcome; there was, however, a significant effect with inclusion
of a trial variable.
Figure 1 shows the probability of mortality at 6 months as a
function of baseline EF for patients with and without a clinical
history of CHF. Patients with a heart failure history undergo-
ing a percutaneous intervention, especially patients with an EF
less than 45%, were at greater risk of death than those without
such a history.
Discussion
A history of CHF is a marker for reduced survival in many
different clinical settings, as is EF. This study confirms the
prognostic importance of both EF and a history of CHF in
5,260 patients undergoing percutaneous revascularization pro-
cedures, as noted in other studies (18,20,22–25). The most
important finding in the present study, however, is not only
that a history of CHF was predictive of mortality, but that it
also added significant information to that already provided by
a patient’s EF. This suggests that for a given EF (Fig. 1), a
patient undergoing a percutaneous intervention with a history
of CHF is at greater risk of intermediate-term mortality than
one without such a history. This difference appears to become
more pronounced at lower EFs.
Prognostic significance of CHF history. Few studies have
assessed the prognostic significance of heart failure history in
those undergoing angioplasty, and none has addressed its
contribution after adjusting for EF. In an analysis of differ-
ences in outcome after angioplasty between men and women,
the hazard ratio for long-term mortality with a history of CHF
was 2.6 (p 5 0.0001) with EF in the model, and 2.94 (p ,
0.0001) without it (31). The contribution of EF when included
in the model containing a history of heart failure suggests that
it adds prognostically to the latter. The reverse analysis,
however, was not reported. In another regression analysis,
CHF history and left ventricular EF were both strong predic-
tors of mortality (risk ratios 3.0 and 3.3, respectively) (23), but
both variables appeared to be in the model together, and the
contribution of each, when adjusted for the other factor, was
not evaluated. In the NHLBI PTCA registry (24), a history of
CHF was the strongest correlate of 4-year mortality (adjusted
risk 4.33, 95% confidence interval 2.67, 7.02). When the 8-year
Table 4. Univariable Outcomes
History of Congestive Heart Failure
Yes
(n 5 334)
No
(n 5 4,926) p
30-day
Death 8 (2%) 29 (,1%) 0.002
Infarction 15 (4%) 308 (6%) NS
Angioplasty 11 (3%) 195 (4%) NS
Bypass surgery 5 (2%) 136 (3%) NS
Composite 35 (10%) 534 (11%) NS
6-Month
Death 17 (5%) 57 (1%) , 0.001
Infarction 21 (6%) 350 (7%) NS
Angioplasty 40 (12%) 594 (12%) NS
Bypass surgery 12 (4%) 249 (5%) NS
Composite 75 (22%) 1,020 (21%) NS
Values are number of patients (percentages).
Table 5. Multivariable Analysis
30-Day 6-Month
Chi-square p Chi-square p
Death
EF alone 34.4 0.0001 54.9 0.0001
CHF history alone 9.4 0.002 21.9 0.0001
CHF added to EF 1.6 0.2 6.3 0.01
EF added to CHF 26.6 0.0001 39.4 , 0.0001
CHF 5 history of congestive heart failure; EF 5 ejection fraction.
Table 6. Predictors of 6-Month Mortality by Stepwise
Logistic Regression
Odds Ratio 95% CI
CHF History 1.9 1.1 to 3.5
EF* 0.8 0.6 to 0.9
Age** 1.7 1.3 to 2.2
No. of diseased vessels 1.3 1.0 to 1.9
*Odds ratio and confidence intervals for each 5% change in ejection fraction.
**Odds ratio and confidence intervals for each 10 years of age. CHF 5 history
of congestive heart failure; CI 5 confidence interval; EF 5 ejection fraction.
Table 3. Angiographic Outcomes
History of Congestive Heart Failure
Yes
(n 5 334)
No
(n 5 4,926)
Device used
Atherectomy 33% 22%
Perfusion balloon 5% 12%
Angioplasty 63% 66%
Multiple devices 12% 11%
Number of lesions attempted
1 260 (79%) 3,823 (79%)
2 60 (18%) 797 (16%)
3 7 (2%) 197 (4%)
4 3 (1%) 53 (1%)
Successful procedure* 274 (83%) 4,102 (84%)
Abrupt closure
In-laboratory 14 (4%) 193 (4%)
In-hospital** 8 (5%) 114 (6%)
6-month restenosis** 44 (46%) 561 (47%)
Values are number of patients (percentages). *Residual stenosis #50%.
**Data not collected in IMPACT-II.
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follow-up of these patients was available, CHF history was
again the risk factor most strongly associated with adverse
events, regardless of the end point (death, death/infarction,
death/infarction/bypass surgery) (24). The independent contri-
butions of EF and heart failure history were not reported in
these studies.
Previous studies. The clinical characteristics of patients in
this cohort were similar to those series previously reported
(20,31–34). Procedural success was 80% in both groups in this
study. While at first this may seem low, it is consistent with
published data. An 84% success rate was reported in 427
patients who underwent angioplasty in 1981 (32), and other
estimates have ranged from 82% to 88% during this time
period (20,33,34). The lower rate seen in our study reflects the
large number of angioplasty patients in this cohort from
CAVEAT-I and -II who had significantly lower success rates
(25,26). In addition, all angiograms in the present analysis were
read in a core laboratory with the use of quantitative coronary
angiography techniques; stenoses assessed in this manner tend
to be graded as more severe than those assessed at individual
sites (35) and may partly account for these lower procedural
success rates.
The 6-month outcomes of patients in the current study are
also consistent with previous studies. Mortality rates compare
with those from reports of stable and unstable angina patients
and also from the NHLBI angioplasty registry (33,34).
Myocardial infarction and revascularization rates were also
similar in this study compared with previous publications
(19,22,23,32).
Clinical considerations. Interestingly, even in patients with
mild or no left ventricular dysfunction (EFs .40%), a history
of CHF is associated with an increased probability of short-
term mortality (Fig. 1). As many as 36% to 42% of patients
with the syndrome of CHF have a normal or near-normal
($45%) EF (36,37). Diastolic dysfunction may play a role in
the syndrome of CHF experienced by patients in this analysis,
but its influence on this patient population remains speculative.
Nearly 40% of patients in the history of CHF cohort had
diabetes. Recently published results of the Bypass and Angio-
plasty Revascularization Investigation Trial suggested that
diabetics had a higher 5-year survival with bypass surgery as
compared with angioplasty as the primary mode of revascular-
ization (38). The decision to proceed with surgery as the mode
of revascularization based solely on a history of diabetes,
however, remains controversial (39). This decision algorithm
should likely include the consideration of other factors such as
angiographic descriptors of disease and clinical factors such as
the presence of CHF.
Study limitations. A limitation of this analysis is the short
duration of follow-up: 6 months for the trials included in this
cohort. While the results of our study may not be generalized
to the long-term outcome of patients undergoing percutaneous
procedures, similarities with long-term studies are worth not-
ing. In the regression analysis performed in this study, we
found that EF and heart failure history were both predictors of
short-term mortality, but did not correlate with later infarction
or further revascularization during the follow-up period. In the
NHLBI PTCA registry, EF was correlated with mortality at 4
years but was not significant in predicting the combined end
points of death/infarction or death/infarction/bypass surgery
(23). In this same population, heart failure history was the
strongest predictor of long-term adverse events, including
combined end points, but this appeared to reflect mostly the
differences in mortality (24). Finally, Ruygrok et al. (20) also
noted that EF predicted mortality at 10 years of follow-up but
did not appear to influence rates of myocardial infarction or
the use of angioplasty or bypass surgery.
Another limitation of this analysis is its retrospective de-
sign. While there are known difficulties with retrospective
studies, the present study represents a large patient population
treated at a broad range of hospitals. Further, the patients in
this study were treated with different percutaneous procedures,
and follow-up was systematic and rigorous. While the tech-
niques of percutaneous intervention have been refined over
the last several years, improvements in procedural outcomes
are unlikely to affect the influence of EF and CHF history on
clinical outcomes. Whether these results can be generalized to
the population of patients receiving a stent remains to be
studied.
Conclusions. In conclusion, this study confirms the impor-
tance of baseline EF on the short-term mortality of patients
undergoing angioplasty and other percutaneous procedures. In
this population of patients included in randomized trials and a
registry, a clinical history of heart failure adds prognostic
information to that already contained in a patient’s EF. This
suggests that in selecting a mode of revascularization for
patients with coronary artery disease, one should consider not
only the state of the left ventricle but also the recent symptom
history of the patient. In patients who may not be fully
compensated, as manifested by recent symptoms of heart
failure, the decision to proceed with percutaneous revascular-
ization should be made cautiously.
Figure 1. The probability of mortality within 6 months after percuta-
neous coronary intervention as a function of baseline ejection fraction
in patients with a history of congestive heart failure (solid line, n 5
334) and without a history of congestive heart failure (dashed line, n 5
4,926).
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